Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Shorter unipedal standing time and lower bone mineral density in women with distal radius fractures
Osteoporosis International, 06/30/09
Sakai A et al. – Study demonstrates that unipedal standing time was shorter and bone mineral density (BMD) was lower in women ≥50 years of age with distal radius fractures than those in age-matched women without fractures.
Methods- Aim was to compare unipedal standing time and BMD of women ≥50 yrs of age with distal radius fractures vs age-matched women w/o fractures
- Fracture group: 54 Japanese women with low-energy distal radius fractures resulting from fall
- Non-fracture group: 52 community-dwelling Japanese women w/o fractures
- Unipedal standing time and BMD were measured
- No differences in age and BMI between the 2 groups
- Percentage of women with unipedal standing time <15 s was 44.4% in the fracture group and 13.5% in the non-fracture group
- Respective frequencies for >120 s were 20.4% and 50.0%
- T-score of BMD was lower in the fracture than non-fracture group
- Logistic regression analysis identified unipedal standing time <15 s and T-score <70% as significant factors associated with distal radius fractures
- T-score <70% was significant in subjects <65 yrs
- Unipedal standing time <15 s was significant in those ≥65 yrs
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Cardiovascular diseases and risk of hip fracture
JAMA, 10/23/09
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150mg and risedronate 150mg
Current Medical Research and Opinion, 10/22/09
Sponsor
Article Search
Sponsor


See Latest Articles


